遗传性易栓症基因突变与癌症患者静脉血栓栓塞风险:系统综述与Meta分析
该系统综述与Meta分析检索Medline、EMBASE和Cochrane Central(截至2022年9月),纳入37项系统综述研究和28项Meta分析研究,评估遗传性易栓症基因突变与成人癌症患者静脉血栓栓塞(VTE)风险的关联。结果显示非O血型、凝血因子V Leiden突变和凝血酶原因子II G20210A突变与VTE风险显著升高相关。
要点
- 非O血型癌症患者VTE风险较O血型升高,OR为1.56(95%CI 1.28-1.90)。
- 凝血因子V Leiden突变者VTE风险OR为2.28(95%CI 1.51-3.48)。
- 凝血酶原因子II G20210A突变者VTE风险OR为2.14(95%CI 1.14-4.03)。
核心结论
- 该Meta分析提供证据表明非O血型、凝血因子V Leiden突变和凝血酶原因子II G20210A突变是癌症患者VTE的重要遗传风险因素。
研究设计与样本
- 研究为系统综述与Meta分析,检索Medline、EMBASE和Cochrane Central(2022年9月),纳入37项系统综述研究和28项Meta分析研究,研究对象为接受遗传性易栓症检测的成人癌症患者。
- 两名评价者筛选摘要/全文并使用预后研究质量工具评估研究质量,采用Mantel-Haenszel随机效应模型估计VTE的合并OR及95%CI。
主要发现
- 非O血型癌症患者VTE风险较O血型显著升高,OR为1.56(95%CI 1.28-1.90)。
- 凝血因子V Leiden突变者VTE风险较野生型显著升高,OR为2.28(95%CI 1.51-3.48)。
- 凝血酶原因子II G20210A突变者VTE风险较野生型显著升高,OR为2.14(95%CI 1.14-4.03)。
- 亚甲基四氢叶酸还原酶C677T杂合子和纯合子VTE风险OR分别为1.50(95%CI 1.00-2.24)和1.38(95%CI 0.87-2.22)。
- 纤溶酶原激活物抑制剂-1 4G/5G、血管内皮生长因子A C634G和血管内皮生长因子C2578A突变与VTE无显著关联。
关键数值与推荐
- 非O血型(对比O血型)VTE风险OR为1.56(95%CI 1.28-1.90)。
- 凝血因子V Leiden突变(对比野生型)VTE风险OR为2.28(95%CI 1.51-3.48)。
- 凝血酶原因子II G20210A突变(对比野生型)VTE风险OR为2.14(95%CI 1.14-4.03)。
- 亚甲基四氢叶酸还原酶C677T杂合子VTE风险OR为1.50(95%CI 1.00-2.24),纯合子OR为1.38(95%CI 0.87-2.22)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the general population, individuals with an inherited thrombophilia have a higher risk of thrombosis, but the effect of inherited thrombophilia on the risk of cancer-associated venous thromboembolism (VTE) remains controversial. Our objective was to determine the risk of VTE in cancer patients with inherited thrombophilia. We conducted a systematic review and meta-analysis of studies reporting on VTE after a cancer diagnosis in adult patients who were tested for inherited thrombophilia. In September 2022, we searched Medline, EMBASE, and Cochrane Central. Two reviewers screened the abstracts/full texts and assessed study quality using the Quality in Prognostic Studies tool. We used Mantel-Haenszel random-effects models to estimate pooled odds ratios (OR) of VTE and 95% confidence intervals (95%CI). We included 37 and 28 studies in the systematic review and meta-analysis, respectively. Most studies focused on specific cancer types and hematologic malignancies were rare. The risk of VTE was significantly higher in cancer patients with non-O (compared with O) blood types (OR: 1.56 [95% CI: 1.28-1.90]), Factor V Leiden, and Prothrombin Factor II G20210A mutations compared with wild types (OR: 2.28 [95% CI: 1.51-3.48] and 2.14 [95% CI: 1.14-4.03], respectively). Additionally, heterozygous and homozygous methylenetetrahydrofolate reductase C677T had ORs of 1.50 (95% CI: 1.00-2.24) and 1.38 (95% CI: 0.87-2.22), respectively. Among those with Plasminogen-Activator Inhibitor-1 4G/5G, Vascular Endothelial Growth Factor (VEGF) A C634G, and VEGF C2578A mutations, there was no significant association with VTE. In conclusion, this meta-analysis provided evidence that non-O blood types, Factor V Leiden, and Prothrombin Factor II G20210A mutations are important genetic risk factors for VTE in cancer patients.
引用
- Roy DC, Wang TF, Lun R, et al. Inherited thrombophilia gene mutations and risk of venous thromboembolism in patients with cancer: A systematic review and meta-analysis. Am J Hematol. 2024. PMID: 38291601. doi:10.1002/ajh.27222
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。